Over the past twenty years, Can Too Foundation has funded over 140 early-career cancer researchers in Australia, with thanks to our incredible participants and supporters. This support during the early phase of their careers enabled them to develop track records and leadership skills, setting them up for long-term success in a highly competitive environment.
This Breast Cancer Awareness Month, we reflect on the journey of one of these amazing researchers - Professor David Gallego Ortega.
Funded by CanToo in 2012, David is now a leading cancer researcher and biomedical engineer. He serves as the Head of the School of Biomedical Engineering and the Director of the Single Cell Technology Facility at the University of Technology Sydney.
His career has been marked by groundbreaking work in breast cancer biology, particularly in developing personalised therapies and understanding treatment resistance.
David’s impact in the field of breast cancer
Through pioneering innovations in personalised medicine and immunotherapy, David has advanced strategies for breast cancer treatment. Some of his most notable achievements include:
Development of the ALTEN device: a groundbreaking technology that preserves tumour biopsies in a 3D environment, allowing for rapid and accurate testing of anticancer therapies. This approach enables clinicians to make real-time treatment decisions within weeks, bridging the gap between laboratory research and patient care, particularly for aggressive cancers such as triple-negative breast cancer.
Immunotherapy for triple-negative breast cancer: His research on myeloid-derived suppressor cells (MDSCs) has revealed key mechanisms through which these cells suppress immune responses in breast cancer and promote tumour growth. By precisely targeting MDSCs with therapies that spare healthy immune cells, David and his team are establishing the groundwork for a new generation of immunotherapies that could improve outcomes for patients with aggressive breast cancer types. CanToo continues to support David and his team with this aspect of his research program.
Single-cell genomics expertise: Under his leadership in single-cell genomics, David has offered unprecedented insights into cancer therapy. Understanding drug responses of individual cells within tumours paves the way for more personalised and effective cancer therapies, providing hope to patients around the globe.
Significance of early-career funding
Can Too Foundation's early-career funding in 2012 played a pivotal role in shaping David’s career as a leading cancer researcher. The grant supported his investigation into anti-estrogen therapy resistance in breast cancer, allowing him to explore innovative ideas during a critical phase of his career.
David told us "early funding from CanToo was the cornerstone of my career. It ignited my creativity and empowered me to attract top government grants and forge international collaborations for ground-breaking research."
This initial support allowed him to establish a strong track record, ultimately leading to his current roles as Head of the School of Biomedical Engineering and Director of the Single Cell Technology Facility at the University of Technology Sydney.
“Today, I am proud to mentor young, talented investigators whose dedication strives to improve patient outcomes. Just like me, they need that jump start in their careers to spark their innovation.”
CanToo’s investment not only jump-started David’s career, but also contributed to advancements in cancer treatment strategies that continue to benefit patients worldwide.
“The work of CanToo and their critical support to young researchers not only boosts talent but gives hope, it creates a legacy that is transforming cancer outcomes for generations to come. This journey is more than just scientific breakthroughs; it’s about uniting everyone in the fight against a disease that touches us all.”
Thank you to our community of CanToo-ers who make research opportunities a reality. To support our ongoing work, including the funding of future cancer research projects, please consider making a donation today, or join a CanToo training program to challenge yourself, while challenging cancer too.
